In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.
PTC Therapeutics's net-net working capital per share for the quarter that ended in Mar. 2022 was $-16.66.
The industry rank for PTC Therapeutics's Net-Net Working Capital or its related term are showing as below:
PTC Therapeutics Net-Net Working Capital Historical Data
The historical data trend for PTC Therapeutics's Net-Net Working Capital can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
|
PTC Therapeutics Annual Data
|
|
Trend |
Dec12 |
Dec13 |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
| Net-Net Working Capital |
|
|
|
|
|
|
-0.20 |
-9.52 |
-4.71 |
-8.04 |
-15.14 |
|
PTC Therapeutics Quarterly Data
|
|
Jun17 |
Sep17 |
Dec17 |
Mar18 |
Jun18 |
Sep18 |
Dec18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
| Net-Net Working Capital |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
-10.68 |
-12.01 |
-13.50 |
-15.14 |
-16.66 |
Competitive Comparison
For the Biotechnology subindustry, PTC Therapeutics's Net-Net Working Capital, along with its competitors' market caps and Net-Net Working Capital data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PTC Therapeutics Net-Net Working Capital Distribution
For the Biotechnology industry and Healthcare sector, PTC Therapeutics's Net-Net Working Capital distribution charts can be found below:
* The bar in red indicates where PTC Therapeutics's Net-Net Working Capital falls into.
PTC Therapeutics Net-Net Working Capital Calculation
PTC Therapeutics's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2021 is calculated as
PTC Therapeutics's Net-Net Working Capital (NNWC) per share for the quarter that ended in Mar. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.
In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
This is a conservative way of estimating the company's value.
PTC Therapeutics Business Description
Traded in Other Exchanges
Address
100 Corporate Court, South Plainfield, NJ, USA, 07080
PTC Therapeutics Inc is a global biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when a RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
Executives
| Southwell David P |
director |
C/O INOTEK PHARMACEUTICALS CORPORATION 91 HARTWELL AVENUE LEXINGTON MA 02421 |
| Jacobson Allan Steven |
director |
PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
| Peltz Stuart Walter |
director, officer: Chief Executive Officer |
PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
| Utter Christine Marie |
officer: SVP, Finance & CAO |
C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
| Boulding Mark Elliott |
officer: Exec. VP and CLO |
C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
| Hill Emily Luisa |
officer: Chief Financial Officer |
C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
| Svoronos Dawn |
director |
C/O MEDIVATION, INC. 525 MARKET ST., 36TH FLOOR SAN FRANCISCO CA 94105 |
| Pauwels Eric |
officer: Chief Business Officer |
550 HILLS DRIVE BEDMINSTER NJ 07921 |
| Klein Matthew B. |
officer: Chief Development Officer |
C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
| Schmertzler Michael |
director |
1300 VALLEY ROAD NEW CANAAN CT 06840 |
| Souza Marcio |
officer: Chief Operating Officer |
C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
| Almstead Neil Gregory |
officer: Chief Technical Ops Officer |
C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
| Reeve Emma |
director |
C/O PAREXEL INTERNATIONAL CORPORATION 195 WEST STREET WALTHAM MA 02451 |
| Steele Glenn Jr Md Phd |
director |
250 TECHNOLOGY PARK LAKE MARY FL 32746-6232 |
| Zeldis Jerome B |
director |
8767 E. VIA DE VENTURA, SUITE 190 SCOTTSDALE AZ 85258 |
PTC Therapeutics Headlines
By Seekingalpha 2021-02-26
By Seekingalpha 2020-10-30
By Seekingalpha 2022-01-12
By Seekingalpha 2022-02-23
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
1.06(3.44%) Volume: 411,550 10:08PM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:PTCT has been successfully added to your 